Gakis Georgios, Schubert Tina, Alemozaffar Mehrdad, Bellmunt Joaquim, Bochner Bernard H, Boorjian Steven A, Daneshmand Siamak, Huang William C, Kondo Tsunenori, Konety Badrinath R, Laguna Maria Pilar, Matin Surena F, Siefker-Radtke Arlene O, Shariat Shahrokh F, Stenzl Arnulf
Department of Urology, University Hospital Tübingen, Hoppe-Seyler Street 3, 72076, Tübingen, Germany.
USC/Norris Comprehensive Cancer Center, Institute of Urology, Los Angeles, CA, USA.
World J Urol. 2017 Mar;35(3):327-335. doi: 10.1007/s00345-016-1819-1. Epub 2016 Apr 4.
To provide a comprehensive overview and update of the joint consultation of the International Consultation on Urological Diseases (ICUD) and Société Internationale d'Urologie for the treatment of localized high-risk upper tract urothelial carcinoma (UTUC).
A detailed analysis of the literature was conducted reporting on treatment modalities and outcomes in localized high-risk UTUC. An international, multidisciplinary expert committee evaluated and graded the data according to the Oxford System of Evidence-based Medicine modified by the ICUD.
Radical nephroureterectomy (RNU) is the standard of treatment for high-grade or clinically infiltrating UTUC and includes the removal of the entire kidney, ureter and ipsilateral bladder cuff. The distal ureter can be managed either by extravesical or transvesical approach, whereas endoscopically assisted procedures are associated with decreased intravesical recurrence-free survival. Post-operative intravesical chemotherapy decreases the risk of subsequent bladder tumour recurrence. Regional lymph node dissection is of prognostic importance in infiltrative UTUC, but its extent has not been standardized. Renal-sparing surgery is an option for manageable, high-grade tumours of any part of the upper tract, especially of the distal ureter, as an alternative to RNU. Endoscopy-based renal-sparing procedures are associated with a higher risk of recurrence and progression.
A multimodal approach should be considered in localized high-risk UTUC to improve outcomes. RNU is the standard of treatment in high-risk disease. Renal-sparing approaches may be oncologically equivalent alternatives to RNU in well-selected patients, especially in those with distal ureteric tumours.
全面概述并更新国际泌尿系统疾病咨询委员会(ICUD)和国际泌尿外科学会关于局限性高危上尿路尿路上皮癌(UTUC)治疗的联合咨询意见。
对关于局限性高危UTUC治疗方式及结果的文献进行详细分析。一个国际多学科专家委员会根据ICUD修改后的牛津循证医学体系对数据进行评估和分级。
根治性肾输尿管切除术(RNU)是高级别或临床浸润性UTUC的治疗标准,包括切除整个肾脏、输尿管及同侧膀胱袖口。远端输尿管可通过膀胱外或经膀胱途径处理,而内镜辅助手术与膀胱内无复发生存率降低相关。术后膀胱内化疗可降低后续膀胱肿瘤复发风险。区域淋巴结清扫对浸润性UTUC的预后具有重要意义,但其范围尚未标准化。保留肾手术是上尿路任何部位可处理的高级别肿瘤的一种选择,特别是远端输尿管肿瘤,可作为RNU的替代方案。基于内镜的保留肾手术与复发和进展风险较高相关。
对于局限性高危UTUC,应考虑采用多模式方法以改善治疗结果。RNU是高危疾病的治疗标准。在精心挑选的患者中,尤其是远端输尿管肿瘤患者,保留肾方法可能在肿瘤学上等同于RNU。